- Home
- EBMT vs CHRS Comparison
EBMT vs CHRS Comparison
Compare EBMT & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EBMT | CHRS |
|---|---|---|
| Founded | 1922 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.7M | 159.1M |
| IPO Year | 2009 | 2014 |
Fundamental Metrics
Financial Performance| Metric | EBMT | CHRS |
|---|---|---|
| Price | $20.86 | $1.01 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $24.00 | $7.75 |
| AVG Volume (30 Days) | 22.0K | ★ 1.7M |
| Earning Date | 10-27-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.85% | N/A |
| EPS Growth | 53.23 | ★ 472.00 |
| EPS | ★ 0.98 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.89 | $44.19 |
| Revenue Next Year | $3.84 | $65.06 |
| P/E Ratio | $21.10 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.80 | $0.97 |
| 52 Week High | $24.66 | $2.62 |
Technical Indicators
Market Signals| Indicator | EBMT | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 37.19 | 36.72 |
| Support Level | $20.00 | $0.97 |
| Resistance Level | $22.84 | $1.53 |
| Average True Range (ATR) | 0.72 | 0.07 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 30.73 | 16.02 |
Price Performance
Historical ComparisonAbout EBMT Eagle Bancorp Montana Inc.
Eagle Bancorp Montana Inc operates as a bank holding company. It provides loan and deposit services. The company focuses on residential loans, commercial real estate loans, commercial loans, consumer loans, and home equity loan products. The bank also offers deposit accounts which include checking, savings, money market, individual retirement accounts, and certificates of deposit accounts. It is a diversified lender with a focus on residential mortgage loans, commercial real estate mortgage loans, commercial business loans, agricultural loans, and second mortgage/home equity loan products.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.